This listing of the claims will replace all prior versions and listings of claims in the application:

Listing of the claims:

Claim 1 (currently amended): A ~~pressure-sensitive adhesive composition for use as a~~ percutaneous absorption preparation which comprises:

(a) ~~a drug~~ one or more drugs, and

(b) polyisoprene,

(c) a styrene/isoprene/styrene copolymer, and

(d) solid polyisobutylene, in a proportion of ~~(15-50)/(25-50)/(30-50)~~ (10-60)/(10-50)/(20-60) parts by weight relative to the total weight of (b), (c) and (d) and further contains a non-solid isobutylene polymer and a ~~petroleum resin type~~ tackifier, characterized in that the amount of the non-solid isobutylene polymer is 5 to 25 parts by weight per 100 parts by weight of the sum of (b), (c) and (d), wherein the content of the ~~petroleum resin type~~ tackifier is in a proportion of 10-80 parts by weight relative to the total weight of (b), (c) and (d), thereby exhibiting a removal resistance to water.

Claim 2 (currently amended): The ~~pressure-sensitive adhesive composition~~ percutaneous absorption preparation

according to ~~claim 1~~ claim 13, wherein the viscosity average molecular weight of the solid polyisobutylene is not less than 900,000 and the viscosity average molecular weight of the non-solid polyisobutylene is not more than 70,000.

Claims 3-7 (canceled)

Claim 8 (currently amended): The ~~pressure-sensitive adhesive composition~~ percutaneous absorption preparation according to ~~claim 1~~ claim 13, wherein the ~~drug is~~ one or more drugs comprise a skin irritant, an analgesic-antiinflammatory agent, an antifungal agent, a centrally acting drug, a diuretic agent, a hypotensor, a coronary vasodilator, an antitussive-expectorant agent, an anti-histaminic agent, an anxiolytic, a cardiotonic agent, a contraceptive, an adrenal hormone ~~or~~ and/or a local anesthetic.

Claim 9 (currently amended): The ~~pressure-sensitive adhesive composition~~ percutaneous absorption preparation according to ~~claim 1~~ claim 13, wherein a liner of the ~~pressure-sensitive adhesive composition~~ percutaneous absorption preparation is a film, a sheet or a foil of polyethylene, polypropylene, a polyester selected from

absorption preparation is a film, a sheet or a foil of polyethylene, polypropylene, a polyester selected from polyethylene terephthalate (PET) or polyethylene napthalate, nylon, aluminium, or paper, or a laminate material thereof.

Claim 10 (currently amended): The ~~pressure-sensitive adhesive composition~~ percutaneous absorption preparation according to ~~claim 8~~ claim 13, wherein the ~~drug is~~ one or more drugs further comprises methyl salicylate, L-menthol and/or dl-camphor.

Claim 11 (new): The percutaneous absorption preparation according to claim 13, wherein the one or more drugs comprise a skin irritant, an analgesic-antiinflammatory agent, a centrally acting drug, a hypotensor, a coronary vasodilator, an antitussive-expectorant agent, an anti-histaminic agent, an anxiolytic, a cardiotonic agent, a contraceptive, an adrenal hormone and/or a local anesthetic.

Claim 12 (new): The percutaneous absorption preparation according to claim 1 wherein the tackifier is petroleum resin and the petroleum resins as the tackifier is in a proportion of 10-80 parts by weight relative to the total weight of (b), (c) and (d).

Claim 13 (new): The percutaneous absorption preparation according to claim 12, which comprises (b), (c) and (d) in a proportion of (15-50)/(25-45)/(30-50) parts by weight relative to the total weight of (b), (c) and (d).

Claim 14 (new): The percutaneous absorption preparation according to claim 1, which has a tackiness of a probe tack value in the range of 20-150 gf and a 180° removal in the range of 20-200 gf.

Claim 15 (new): The percutaneous absorption preparation according to claim 1, which reduces irritation to skin.

Claim 16 (new): The percutaneous absorption preparation according to claim 14, which reduces irritation to skin.

Claim 17 (new): A method for obtaining in a percutaneous absorption preparation applied to skin a tackiness of a probe tack value in the range of 20-150 gf and a 180° removal in the range of 20-200 gf, thereby exhibiting removal resistance in water while reducing skin irritation, said method comprising administering to the skin the percutaneous absorption preparation of claim 1.